Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Dexamethasone + Isatuximab + Lenalidomide |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Dexamethasone | Adexone | Desametasone | ||
| Isatuximab | Sarclisa | SAR650984|isatuximab-irfc | CD38 Antibody 20 | Sarclisa (isatuximab-irfc) is a humanized monoclonal antibody against CD38 that induces anti-tumor immune reaction against CD38-positive tumor cells (PMID: 24987056). Sarclisa (isatuximab-irfc) in combination with Pomalyst (pomalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received two or more prior therapies, and in combination with Kyprolis (carfilzomib) and dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy (FDA.gov). |
| Lenalidomide | Revlimid | IMiD-1 | Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05145400 | Phase II | Dexamethasone + Isatuximab + Lenalidomide | Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | Recruiting | USA | 0 |
| NCT04751877 | Phase III | Dexamethasone + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Study of Isatuximab+Lenalidomide+Dexamethasone With/Without Bortezomib in de Novo Non Frail NTE Multiple Myeloma Elderly Patients (IFM2020-05) | Active, not recruiting | FRA | 0 |
| NCT04891809 | Phase II | Dexamethasone + Isatuximab + Lenalidomide Dexamethasone + Lenalidomide | Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged >=70 Years) With NDMM | Recruiting | AUT | 2 |
| NCT03319667 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ) | Active, not recruiting | USA | NZL | ITA | FRA | ESP | DEU | BEL | AUS | 13 |
| NCT04270409 | Phase III | Dexamethasone + Lenalidomide Dexamethasone + Isatuximab + Lenalidomide | Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma | Active, not recruiting | USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 15 |
| NCT05690984 | Phase II | Dexamethasone + Isatuximab + Lenalidomide | Elimination of Minimal Residual Disease After Transplant (EMAT) | Recruiting | USA | 0 |
CKB BOOST